The injection FZ-P001 sodium developed by Fudan Zhangjiang (01349) for visualizing malignant lesions in ovarian cancer surgery has completed the first subject enrollment in Phase I clinical trial.

FUDANZHANGJIANG (01349) announced that the phase I clinical trial of the injectable sodium FZ-P001, developed by the company for visualizing malignant lesions in ovarian cancer surgery, has successfully enrolled the first subject. It is reported that the injectable sodium FZ-P001 is a chemically synthesized Class 1 new compound independently developed by the company. It is an innovative photosensitizer, with its active ingredient being a molecule formed by the coupling of a folate receptor-targeted small molecule with a phthalocyanine photosensitizer, which can target malignant tumor tissues with high expression of folate receptor (FR) and fluoresce in the near-infrared range. Among the three major gynecological malignant tumors, ovarian cancer has the highest mortality rate, posing a serious threat to women's health. The company plans to use this drug to develop intraoperative fluorescence-guided technology to indicate the presence of residual malignant tissues and the status of margins, aiming to improve the surgical resection effectiveness of relevant solid tumors and provide an innovative solution for precise navigation surgery in oncology, with both molecular targeting specificity and multidimensional biological sensing capabilities.